Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study

Oliver Meyer; Raymond S.M. Wong; Abderrahim Khelif; Miona Stankovic; Joan Maier; Mansoor N. Saleh; James B. Bussel

doi:10.1111/bjh.17800

Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study

Oliver Meyer, Raymond S.M. Wong, Abderrahim Khelif, Miona Stankovic, Joan Maier, Mansoor N. Saleh, James B. Bussel

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	448-452
Number of pages	5
Journal	British Journal of Haematology
Volume	196
Issue number	2
DOIs	https://doi.org/10.1111/bjh.17800
Publication status	Published - Jan 2022
Externally published	Yes

Access to Document

10.1111/bjh.17800

Cite this

@article{5b72a725506848e3bca209cfff7f02b0,

title = "Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study",

author = "Oliver Meyer and Wong, {Raymond S.M.} and Abderrahim Khelif and Miona Stankovic and Joan Maier and Saleh, {Mansoor N.} and Bussel, {James B.}",

note = "Funding Information: This study was sponsored by Novartis. The authors thank Azura Charles, MSc, and Shilu Amin, PhD, of Chameleon Communications, London, UK, for providing medical writing support, which was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). ",

year = "2022",

month = jan,

doi = "10.1111/bjh.17800",

language = "English",

volume = "196",

pages = "448--452",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab

T2 - post-hoc analysis of the EXTEND study

AU - Meyer, Oliver

AU - Wong, Raymond S.M.

AU - Khelif, Abderrahim

AU - Stankovic, Miona

AU - Maier, Joan

AU - Saleh, Mansoor N.

AU - Bussel, James B.

N1 - Funding Information: This study was sponsored by Novartis. The authors thank Azura Charles, MSc, and Shilu Amin, PhD, of Chameleon Communications, London, UK, for providing medical writing support, which was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ).

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85113804973&partnerID=8YFLogxK

U2 - 10.1111/bjh.17800

DO - 10.1111/bjh.17800

M3 - Letter

C2 - 34458977

AN - SCOPUS:85113804973

SN - 0007-1048

VL - 196

SP - 448

EP - 452

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study

Access to Document

Other files and links

Cite this